Japan's aRigen, S. Korea's Green Cross Co-Develop MRSA Antibiotic
This article was originally published in PharmAsia News
Executive Summary
Japan's aRigen Pharmaceuticals and South Korea's Green Cross have agreed to co-develop an antibiotic against methicillin-resistant staphylococcus aureus in Asia